FDA Approves New Option in Obesity - Top_Thought_Leaders - MDSpire

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.

  • By

  • Kathryn Wighton

  • February 23, 2026

  • 3 min

Share

Top Thought Leaders in Pathology

Brief introduction explaining scope and methodology.

Original Source(s)

FDA Approves New Option in Obesity

  • by Kathryn Wighton

  • February 23, 2026

Related Content

Correlation between cardiorespiratory fitness and body composition in individuals with different glucose metabolism statuses

3 Medical Routines That Older People May Not Need

“The treatment may be more burdensome than the condition itself."

Visceral fat area and visceral-to-subcutaneous fat ratio are more strongly associated with residual cholesterol than conventional anthropometric indices in adults with type 2 diabetes